


cancertrack™

Blood based monitoring for all
solid organ tumours



For professional use only



About cancertrack™


cancertrack™ is a minimally-invasive blood-based investigation that detects cancer derived biomarkers with ultra-high precision, specificity and reliability. It analyses ctDNA, CTCs and/or exosomes in the course of cancer. Recurrences or disease progression can thus be detected as early as possible and therapy can be adjusted.

cancertrack™ can be used to monitor the disease / recurrence or changes in the tumour characteristics, as often as necessary.

Features of cancertrack™

- Multi-coordinate and multidimensional probes to track down DNA released by cancer cells in the patient's blood
- Unique, unprecedented capability to detect cancerous activity
- Real-time adjustment of the medication based on the test results
- Safe, sure, simple and cost-effective
- Minimally-invasive blood test
- Rapid lab result
- Tests all active disease sites
- Limits of detection is 0.1% Mutant Allele Frequency

Analytes



Analytes	cancertrack™
Panel	52 genes
SNVs	42 genes
Gene Fusions	12 genes
CNVs	12 genes

cancertrack™ is suitable for



... every patient who is under treatment for cancer.




Every patient who is in remission / a cancer survivor and needs monitoring.



... every person who has been diagnosed with cancer, as a supplement to conventional biopsy for a more robust molecular diagnosis and baseline measurement of cell-free tumour DNA and CTC values before initiation of therapy.

Keeping track of cancer is very critical

Optimally, the treatment is always one step ahead of the cancer. cancertrack™ ensures real-time monitoring to detect genetic changes in the tumor at an early stage. Clinically relevant mutations can thereby be monitored, or medication can be aligned with the results.



FAQ's



How is cancertrack™ validated?

cancertrack™ has been validated clinically on several hundred samples and the process validation meets and exceeds the claimed sensitivity and specificity. cancertrack™ has a combined sensitivity of 99.28% and a positive predictive value of 100%.



Why is early detection of molecular dynamics of cancer critical?

The rapid and continuous evolution of the molecular profile of tumours results in tumour heterogeneity, which confers significant survival benefits on the tumour. cancertrack™ unravels these molecular features in real time to identify critical signs linked to recurrence or emerging drug resistance as well as novel vulnerabilities, which empowers the treating clinician to avail optimum treatment strategies to intercept such cancers in a timely manner.



How frequently is it necessary to do the test?

cancertrack™ should ideally be performed at every important milestone in the fight against cancer and especially when the tumour has disappeared from conventional imaging / patient is under follow-up for recurrence monitoring.



What are the limitations of cancertrack™?

While cancertrack™ is extremely robust, like every molecular diagnostic technique, constraints naturally arising due to biological function in an individual patient may impact performance. However, such events are usually averaged out in sequential testing.



Sample requirement:

15–20 ml blood in DCGL tubes

Turn Around Time (TAT):

2 weeks from receipt of the sample

211111-BCTM-EN-WM



Nordic Laboratories

Nordic Laboratories

@nordiclaboratories

Nordic Laboratories & dnalife

Head Office:

Nygade 6, 3.sal
1164 Copenhagen K
Denmark
Tlf: +45 33 75 10 00

South Africa Office:

North Block, Thrupps Centre
204 Oxford Rd, Illove 2196
South Africa
Tel: +27 (0) 11 268 0268

UK Office:

11 Old Factory Buildings, Stonegate
East Sussex, TN5 7DU
United Kingdom
Tel: +44 (0)1580 201 687

info@nordic-labs.com
www.nordic-labs.com